Life Sciences Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN AIT News Desk May 23, 2022 Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines,…